With an identical design and similar eligibility criteria, the DAPHNe and CompassHER2 pCR trials appraised postoperative trastuzumab and pertuzumab with the omission of adjuvant chemotherapy in HER2+ BC patients. Here, ERBB2 is linked to breast cancer.